Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain
Author(s) -
Anutosh Chakraborty,
Michael A. Koldobskiy,
Nicholas T. Bello,
Micah J. Maxwell,
James J. Potter,
Krishna R. Juluri,
David Maag,
Seyun Kim,
Alex S. Huang,
Megan J. Dailey,
Masoumeh Saleh,
Adele M. Snowman,
Timothy H. Moran,
Esteban Mezey,
Solomon H. Snyder
Publication year - 2010
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2010.11.032
Subject(s) - biology , inositol , protein kinase b , signal transduction , insulin sensitivity , microbiology and biotechnology , insulin receptor , pi3k/akt/mtor pathway , insulin , sensitivity (control systems) , inositol phosphate , biochemistry , endocrinology , medicine , insulin resistance , receptor , electronic engineering , engineering
The inositol pyrophosphate IP7 (5-diphosphoinositolpentakisphosphate), formed by a family of three inositol hexakisphosphate kinases (IP6Ks), modulates diverse cellular activities. We now report that IP7 is a physiologic inhibitor of Akt, a serine/threonine kinase that regulates glucose homeostasis and protein translation, respectively, via the GSK3β and mTOR pathways. Thus, Akt and mTOR signaling are dramatically augmented and GSK3β signaling reduced in skeletal muscle, white adipose tissue, and liver of mice with targeted deletion of IP6K1. IP7 affects this pathway by potently inhibiting the PDK1 phosphorylation of Akt, preventing its activation and thereby affecting insulin signaling. IP6K1 knockout mice manifest insulin sensitivity and are resistant to obesity elicited by high-fat diet or aging. Inhibition of IP6K1 may afford a therapeutic approach to obesity and diabetes.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom